awmsg logo



tacrolimus (Advagraf®)


Reference No. 820

Publication date:
07/09/2011


Appraisal information

tacrolimus (Advagraf®) 0.5 mg prolonged-release capsule
tacrolimus (Advagraf®) 1 mg prolonged-release capsule
tacrolimus (Advagraf®) 3 mg prolonged-release capsule
tacrolimus (Advagraf®) 5 mg prolonged-release capsule


Company: Astellas Pharma Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/05/2011
AWMSG meeting date: 15/06/2011
   
   
Submission Type: Resubmission
Status: Recommended with restrictions
Advice No: 0811
Ministerial ratification: 01/09/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tacrolimus (Advagraf®) is recommended as an option for restricted use within NHS Wales for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Tacrolimus (Advagraf®) is not recommended for use within NHS Wales for the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. Tacrolimus (Advagraf®) should be prescribed by brand name to reduce the risk of medication errors. AWMSG is of the opinion that tacrolimus (Advagraf®) may be suitable for shared care for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download